Stephen D. Griffin net worth and biography

Stephen Griffin Biography and Net Worth

CEO of Anika Therapeutics

Steve Griffin was appointed President and Chief Executive Officer in February 2026. Prior to his current role, Mr. Griffin was the Executive Vice President, Chief Financial Officer and Chief Operating Officer at Anika since April 2025 after joining the company in June 2024. He brings more than 15 years of experience in senior finance leadership roles and a proven track record of value creation at both large- and small-cap companies. Prior to joining Anika, Mr. Griffin most recently served as Senior Vice President and Chief Financial Officer at VSE Corporation, where he helped execute a strategic transformation of a 60 year-old company through organic growth, six acquisitions, and two divestitures. In this role he was responsible for all finance, investor relations and corporate IT functions. Prior to his tenure with VSE Corporation, Mr. Griffin spent over a decade at General Electric in positions of increasing responsibility including Corporate Audit, Financial Planning and Analysis, and Divisional CFO roles. At GE, Steve worked across GE Healthcare, GE Aerospace, and GE Power, and he is also a graduate of GE’s financial management program.

Mr. Griffin holds a B.S. in Finance and Accounting from Boston College and an MBA with high distinction from the University of Michigan.

What is Stephen D. Griffin's net worth?: The estimated net worth of Stephen D. Griffin is at least $544.61 thousand as of April 30th, 2026. Griffin owns 36,163 shares of Anika Therapeutics stock worth more than $544,615 as of July 20th. This net worth estimate does not reflect any other assets that Griffin may own. Learn More about Stephen D. Griffin's net worth.
How do I contact Stephen D. Griffin?: The corporate mailing address for Griffin and other Anika Therapeutics executives is 32 WIGGINS AVENUE, BEDFORD MA, 01730. Anika Therapeutics can also be reached via phone at (781) 457-9000 and via email at [email protected]. Learn More on Stephen D. Griffin's contact information.
Has Stephen D. Griffin been buying or selling shares of Anika Therapeutics?: Stephen D. Griffin has not been actively trading shares of Anika Therapeutics in the last ninety days. Most recently, on Thursday, April 30th, Stephen D. Griffin bought 12,200 shares of Anika Therapeutics stock. The stock was acquired at an average cost of $12.29 per share, with a total value of $149,938.00. Following the completion of the transaction, the chief executive officer now directly owns 36,163 shares of the company's stock, valued at $444,443.27. Learn More on Stephen D. Griffin's trading history.
Who are Anika Therapeutics' active insiders?: Anika Therapeutics' insider roster includes Stephen Griffin (CEO), John Hennemann, III (Director), Raymond Land (Director), and Michael Levitz (CFO). Learn More on Anika Therapeutics' active insiders.
Are insiders buying or selling shares of Anika Therapeutics?: In the last year, Anika Therapeutics insiders bought shares 2 times. They purchased a total of 17,200 shares worth more than $223,238.00. The most recent insider tranaction occured on May, 1st when Director John B Henneman III bought 5,000 shares worth more than $73,300.00. Insiders at Anika Therapeutics own 12.1% of the company. Learn More about insider trades at Anika Therapeutics.
Information on this page was last updated on 5/1/2026.

Stephen D. Griffin Insider Trading History at Anika Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/30/2026	Buy	12,200	$12.29	$149,938.00	36,163

Stephen D. Griffin Buying and Selling Activity at Anika Therapeutics

Anika Therapeutics Company Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $15.06

$14.93

$15.76

50 Day Range

MA: $14.98

$14.20

$16.34

2 Week Range

Now: $15.06

$7.87

$16.49

Volume

52,809 shs

Average Volume

72,042 shs

Market Capitalization

$200.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23